Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

January 27, 2026
Otsuka Pharmaceutical

Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
January 26, 2026
Otsuka Pharmaceutical

Otsuka Pharmaceutical Begins Rollout of PET Bottles Made from 100% Recycled PET Resin Aiming to Realize a Decarbonized and Circular Society
January 21, 2026
Otsuka Pharmaceutical

Otsuka and Towa Conclude Basic Agreement on the Succession and Manufacturing Outsourcing of Long Listed Products, Establishing a Collaborative Framework for Stable Supply
January 21, 2026
Otsuka Pharmaceutical

Dawnzera (donidalorsen) granted European Union marketing authorisation for the prevention of hereditary angioedema
January 19, 2026
Otsuka Pharmaceutical

Otsuka Pharmaceutical Expands On-Site Solar Power Facilities at Factory Premises Accelerating Carbon-Neutral Initiatives
January 14, 2026
Otsuka Holdings

Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
January 6, 2026
Otsuka Holdings

Otsuka Group Introduces Wind Power Derived Electricity as “Self-Generated Renewable Energy” to Promote Carbon Neutrality Initiatives
January 5, 2026
Taiho Pharmaceutical

Sanofi and Taiho Announce Sales Transfer of Anticancer Agent JEVTANA® Intravenous Infusion 60 mg
December 22, 2025
Otsuka Foods

Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of March 1, 2026
December 19, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Supports Anti-Doping Initiative “CLEAN SPORT NIPPON SELECT”
December 19, 2025
Otsuka Pharmaceutical

Otsuka Initiates Global Phase 3 Clinical Trial Evaluating Repinatrabit for the Treatment of Phenylketonuria (PKU)
December 13, 2025
Taiho Pharmaceutical

Results of the Phase 3 STAR-221 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab
December 2, 2025
Otsuka Pharmaceutical

Otsuka Launches Frailty Prevention Support VR as Newest Content in FACEDUO VR Program Portfolio -Enables earlier detection of frailty to support health maintenance and prevent or defer the need for nursing care-
November 28, 2025
Taiho Pharmaceutical

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information ~Development of Shared Neoantigen Cancer Vaccines~
November 26, 2025
Otsuka Pharmaceutical

Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
November 25, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
November 21, 2025
Otsuka Pharmaceutical

Otsuka launches NEXLETOL in Japan
November 21, 2025
Taiho Pharmaceutical

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of NDA to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
November 17, 2025
Otsuka Foods

Otsuka Foods Receives “Special Award” in the Food and Culture Awards,a First for a Food Manufacturer Recognized for Development Capabilities and Contributions as a Pioneer in Retort Foods
November 17, 2025
Otsuka Pharmaceutical

Donidalorsen Receives Positive CHMP Opinion for the Prevention of Hereditary Angioedema Attacks
November 10, 2025
Otsuka Holdings

Otsuka Group Establishes Solar Power Generation Facility in Donari, Tokushima as Its First Off-Site PPA Project to Promote Carbon Neutrality Initiatives
November 10, 2025
Otsuka Pharmaceutical

Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025 Showed Proteinuria Reduction through 12 Months for the Treatment of Immunoglobulin A Nephropathy (IgAN)
November 6, 2025
Otsuka Pharmaceutical

Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis
November 5, 2025
Otsuka Pharmaceutical

Otsuka Signs Joint Research Agreement in Japan with National Cerebral and Cardiovascular Center —Purpose Is to Evaluate Salt Reduction Behavior Change in Heart Disease Patients Using a Nutritional Monitoring App—
October 31, 2025
Otsuka Pharmaceutical

Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) ‐ Acquires Exclusive Development and Commercialization Rights for Asia-Oceania Region, Including Japan, from 4DMT ‐
October 31, 2025
Otsuka Medical Devices

Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 Months with Recor Medical’s Paradise Ultrasound Renal Denervation System (link to Recor website)
October 29, 2025
Otsuka Medical Devices

CMS Issues National Coverage Determination for Recor Medical’s Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension (link to Recor website)
October 20, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
October 16, 2025
Taiho Pharmaceutical

Taiho Pharma Enters Into Exclusive License Agreement with Haihe Biopharma for PI3Kα Inhibitor Risovalisib (CYH33)
October 10, 2025
Otsuka Holdings

Otsuka Holdings Publishes “Integrated Report 2025”

Otsuka Group News

First 30 results